|
Volumn 5, Issue 12, 2005, Pages 3019-
|
Is administration of rituximab at 375 mg/m2 without splenectomy appropriate for ABO-incompatible renal transplant? [1]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
15 DEOXYSPERGUALIN;
AZATHIOPRINE;
CD20 ANTIBODY;
CYCLOPHOSPHAMIDE;
LYMPHOCYTE ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PREDNISOLONE;
RITUXIMAB;
TACROLIMUS;
IMMUNOLOGIC FACTOR;
MONOCLONAL ANTIBODY;
BLOOD GROUP ABO INCOMPATIBILITY;
BLOOD TOXICITY;
DOSE RESPONSE;
HUMAN;
JAPAN;
KIDNEY TRANSPLANTATION;
LETTER;
NEUTROPENIA;
PLASMAPHERESIS;
PRIORITY JOURNAL;
SPLENECTOMY;
SURVIVAL RATE;
BLOOD GROUP ABO SYSTEM;
BLOOD GROUP INCOMPATIBILITY;
GRAFT REJECTION;
NOTE;
ABO BLOOD-GROUP SYSTEM;
ANTIBODIES, MONOCLONAL;
BLOOD GROUP INCOMPATIBILITY;
GRAFT REJECTION;
HUMANS;
IMMUNOLOGIC FACTORS;
KIDNEY TRANSPLANTATION;
SPLENECTOMY;
|
EID: 33644816294
PISSN: 16006135
EISSN: 16006143
Source Type: Journal
DOI: 10.1111/j.1600-6143.2005.01088.x Document Type: Letter |
Times cited : (16)
|
References (5)
|